MDT

98.58

+2.77%↑

A

145.93

-0.38%↓

VEEV

220.72

-1.98%↓

HQY

87

+2.64%↑

NEOG

9.6

+3.9%↑

MDT

98.58

+2.77%↑

A

145.93

-0.38%↓

VEEV

220.72

-1.98%↓

HQY

87

+2.64%↑

NEOG

9.6

+3.9%↑

MDT

98.58

+2.77%↑

A

145.93

-0.38%↓

VEEV

220.72

-1.98%↓

HQY

87

+2.64%↑

NEOG

9.6

+3.9%↑

MDT

98.58

+2.77%↑

A

145.93

-0.38%↓

VEEV

220.72

-1.98%↓

HQY

87

+2.64%↑

NEOG

9.6

+3.9%↑

MDT

98.58

+2.77%↑

A

145.93

-0.38%↓

VEEV

220.72

-1.98%↓

HQY

87

+2.64%↑

NEOG

9.6

+3.9%↑

Search

Penumbra Inc

Open

SectorGezondheidszorg

351.27 14.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

302.96

Max

351.75

Belangrijke statistieken

By Trading Economics

Inkomsten

581K

46M

Verkoop

15M

355M

K/W

Sectorgemiddelde

76.246

90.831

Winstmarge

12.927

Werknemers

4,500

EBITDA

4M

55M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.96% upside

Dividenden

By Dow Jones

Volgende Winsten

17 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.7B

13B

Vorige openingsprijs

336.85

Vorige sluitingsprijs

351.27

Nieuwssentiment

By Acuity

50%

50%

151 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Penumbra Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jan 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 jan 2026, 00:00 UTC

Winsten

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 jan 2026, 23:47 UTC

Marktinformatie

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 jan 2026, 23:39 UTC

Marktinformatie

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 jan 2026, 23:32 UTC

Marktinformatie

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 jan 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 jan 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 jan 2026, 22:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 jan 2026, 22:17 UTC

Marktinformatie

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 jan 2026, 22:09 UTC

Winsten

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 jan 2026, 21:52 UTC

Acquisities, Fusies, Overnames

WuXi XDC Announces Positive Profit Alert for 2025

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Citigroup Acting as Financial Advisor to WuXi XDC

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

14 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jan 2026, 21:49 UTC

Acquisities, Fusies, Overnames

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Makes Cash Offer for BioDlink International

14 jan 2026, 21:13 UTC

Marktinformatie

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 jan 2026, 20:30 UTC

Marktinformatie
Winsten

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 jan 2026, 20:13 UTC

Marktinformatie

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 jan 2026, 20:08 UTC

Marktinformatie

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 jan 2026, 19:33 UTC

Marktinformatie

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 jan 2026, 19:06 UTC

Marktinformatie
Winsten

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Vergelijking

Prijswijziging

Penumbra Inc Prognose

Koersdoel

By TipRanks

14.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 346 USD  14.96%

Hoogste 388 USD

Laagste 266 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Penumbra Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technische score

By Trading Central

288.28 / 292.9394Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

151 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat